COMPANY PROFILE

Sunbird Bio

Explore full profile

A Novel Detector of Neurodegenerative Disease

Cambridge, United StatesFounded 2020Biotech & Life Sciences

Valuation $0–100M Latest valuation · 2024

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Sunbird Bio

Sunbird Bio operates in the molecular diagnostics market, focusing on early detection of neurodegenerative diseases and cancer. The company serves healthcare providers and patients by offering advanced diagnostic platforms like APEX and EnVision. APEX is designed to detect protein aggregates linked to neurodegenerative diseases, enabling early diagnosis and monitoring through a simple blood test. EnVision focuses on oncology, providing early detection of cancer biomarkers to improve treatment options and outcomes. Sunbird Bio's business model revolves around selling these diagnostic tests to healthcare institutions and practitioners, generating revenue through test sales and possibly subscription models for continuous monitoring. The company's innovative approach aims to make diagnostic testing faster, more accurate, and more affordable, ultimately improving patient care and healthcare decision-making.

Source: Dealroom company data

At a glance

Status: Operational
Founded: 2020
Headquarters: Cambridge, United States
Employees: 18
Open positions: None listed
Dealroom signal: 60.1/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, proteomics, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Investment activity: 1 company, latest Aug 2023
Capital deployed: —
Preferred round: ACQUISITION
Links: Website LinkedIn

Latest news

Press, funding announcements and product moves mentioning Sunbird Bio.

See all news

Funding history

3 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
EARLY VC✓Equity / VC	Oct 2024	$14M	$56M	EDBI · Eli Lilly	↗
EARLY VCEquity / VC	Jan 2021	$2M	$8M	ClavystBio · Polaris Partners	—

Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Sunbird Bio website traffic

Latest recorded traffic for Sunbird Bio is 1.9K monthly website visits, up 131.7% over the last three months. Sunbird Bio's team declined 52.6% over the past year.

Latest monthly visits1.9K 3-month web change+131.7% 1-year team growth-52.6%

Monthly website visitsDec 2022–Apr 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
CTCyclone TherapeuticsA preclinical-stage drug discovery company that focuses on improving protein quality control by modulating translation	San Diego, United States	Operational	1	$800K	$3.2M
IMImmobazymeImmobazyme is a South African biotechnology spin-out company of Stellenbosch University that utilizes precision fermentation to produce high-value active protein ingredients.	Stellenbosch Local Municipality, South Africa	Operational
MOMoleculeMindA leading AI protein design platform company	Haidian, China	Operational
MAMatchpointDesigning a new era of precision covalent medicines informed by breakthroughs in ultradeep chemoproteomics and machine learning	Boston, United States	Operational
CECellshootSearching for drug discovery target molecules and create groundbreaking new drug candidates	Tokyo, Japan	Operational
PBProteo BridgeIs scheduled to give a presentation at an event called the aist startup pitch	Tokyo, Japan	Operational
ETEngimmune TherapeuticsPlatform and product development company engineering next-generation T cell receptor therapies	Allschwil, Switzerland	Operational
ATAukera TherapeuticsBiotech company that develops novel therapeutics for patients suffering from mTOR protein related diseases	Basel, Switzerland	Operational